J&J says won’t make AIDS drug obvious in Africa



By Ben Hirschler

LONDON |
Thu Nov 29, 2012 9:06am EST


LONDON (Reuters) – Generic manufacturers are to be given a giveaway rein to make inexpensive copies of Johnson Johnson’s HIV/AIDS drug Prezista for sale in Africa and other bad countries.

U.S. medical organisation JJ pronounced on Thursday it would not make patents, supposing general firms done high-quality versions of a drug – famous generically as darunavir – for sub-Saharan Africa and Least Developed Countries.

Prezista is a comparatively new drug used when patients rise insurgency to comparison antiretrovirals. The need for it was approaching to grow fast as some-more patients in Africa stop responding to existent therapies.

Pharmaceuticals conduct Paul Stoffels pronounced he approaching Indian drugmakers, in particular, to take advantage of a obvious move, adding that foe among opposite companies should expostulate prices down further.

JJ has an existent understanding with South African organisation Aspen Pharmacare, that creates Prezista during a ignored cost of $2.22 per day for Africa – a fragment of a western marketplace price.

Its preference to act unilaterally on Prezista patents will, however, defect those job for JJ to share egghead skill rights in a new Medicines Patent Pool, that aims to streamline general prolongation by pooling patents.

“We have selected to go approach … we consider that is a best way,” Stoffels pronounced in an interview.

“We wish to haven a right to strengthen patents if people are not providing a right peculiarity of product, for instance by bringing products to marketplace that under-dose.”

International drugmakers are underneath flourishing vigour to make medicines some-more affordable in bad countries, after being pounded for not doing adequate in a past.

JJ ranked second in a new research of how companies are behaving in providing entrance to medicines – an alleviation of 7 places from dual years earlier, following a squeeze of Crucell, that creates vaccines for a building world.

(Editing by Dan Lalor)

Source: Health Medicine Network